Literature DB >> 16722818

Botulinum toxin type A for the treatment of migraine.

Sheena Aurora1.   

Abstract

Migraine is a common and debilitating disorder that often requires prophylactic therapy, particularly for those migraine patients who meet the diagnostic criteria for chronic daily headache (chronic migraine). Existing prophylactic treatments for migraine are inadequate for many patients due to their modest efficacy and/or systemic side effects. Alternative treatment strategies are needed, particularly in those with chronic migraine. Botulinum toxin type A is a locally injected protein complex that has been investigated as a treatment for episodic migraine and chronic daily headache. A systematic series of controlled trials has led to the identification of a subset of migraineurs with chronic daily headache who obtain demonstrated benefits of botulinum toxin type A over placebo that is maintained with repeated treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722818     DOI: 10.1517/14656566.7.8.1085

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

Review 1.  The Pediatric Trochlear Migraine: Diagnostic and Therapeutic Implications.

Authors:  Vincenzo Raieli; Federica Reina; Daniela D'Agnano; Giovanna Martina Nocera; Mariarita Capizzi; Francesca Marchese; Vittorio Sciruicchio
Journal:  J Clin Med       Date:  2022-05-17       Impact factor: 4.964

2.  Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

Authors:  Stephen D Silberstein; David W Dodick; Sheena K Aurora; Hans-Christoph Diener; Ronald E DeGryse; Richard B Lipton; Catherine C Turkel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-12-12       Impact factor: 10.154

Review 3.  Role of Botulinum Toxin Type-A (BTX-A) in the Management of Trigeminal Neuralgia.

Authors:  Gaurav Verma
Journal:  Pain Res Treat       Date:  2013-10-01

4.  OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

Authors:  S K Aurora; D W Dodick; H-C Diener; R E DeGryse; C C Turkel; R B Lipton; S D Silberstein
Journal:  Acta Neurol Scand       Date:  2013-09-20       Impact factor: 3.209

5.  Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.

Authors:  Modar Khalil; Hassan W Zafar; Victoria Quarshie; Fayyaz Ahmed
Journal:  J Headache Pain       Date:  2014-09-01       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.